nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.0302	0.0878	CbGbCtD
Orlistat—CYP3A4—Trimethadione—epilepsy syndrome	0.0281	0.0817	CbGbCtD
Orlistat—CYP3A4—Felbamate—epilepsy syndrome	0.0281	0.0817	CbGbCtD
Orlistat—CYP3A4—Fosphenytoin—epilepsy syndrome	0.0264	0.0768	CbGbCtD
Orlistat—CYP3A4—Clonazepam—epilepsy syndrome	0.0239	0.0694	CbGbCtD
Orlistat—CYP3A4—Clobazam—epilepsy syndrome	0.0229	0.0666	CbGbCtD
Orlistat—CYP3A4—Rufinamide—epilepsy syndrome	0.0194	0.0566	CbGbCtD
Orlistat—CYP3A4—Carbamazepine—epilepsy syndrome	0.0189	0.0552	CbGbCtD
Orlistat—CYP3A4—Primidone—epilepsy syndrome	0.0177	0.0515	CbGbCtD
Orlistat—CYP3A4—Phenytoin—epilepsy syndrome	0.017	0.0495	CbGbCtD
Orlistat—CYP3A4—Propofol—epilepsy syndrome	0.0159	0.0461	CbGbCtD
Orlistat—CYP3A4—Phenobarbital—epilepsy syndrome	0.0151	0.0441	CbGbCtD
Orlistat—CYP3A4—Acetazolamide—epilepsy syndrome	0.0151	0.0441	CbGbCtD
Orlistat—CYP3A4—Midazolam—epilepsy syndrome	0.0149	0.0435	CbGbCtD
Orlistat—CYP3A4—Diazepam—epilepsy syndrome	0.0144	0.0418	CbGbCtD
Orlistat—CYP3A4—Zonisamide—epilepsy syndrome	0.014	0.0408	CbGbCtD
Orlistat—CYP3A4—Valproic Acid—epilepsy syndrome	0.0113	0.033	CbGbCtD
Orlistat—CYP3A4—Topiramate—epilepsy syndrome	0.0102	0.0297	CbGbCtD
Orlistat—DAGLA—forebrain—epilepsy syndrome	0.00759	0.0841	CbGeAlD
Orlistat—DAGLA—head—epilepsy syndrome	0.00434	0.0482	CbGeAlD
Orlistat—DAGLA—nervous system—epilepsy syndrome	0.00412	0.0457	CbGeAlD
Orlistat—DAGLA—central nervous system—epilepsy syndrome	0.00397	0.044	CbGeAlD
Orlistat—DAGLA—cerebellum—epilepsy syndrome	0.00388	0.043	CbGeAlD
Orlistat—PLA2G7—medulla oblongata—epilepsy syndrome	0.00343	0.038	CbGeAlD
Orlistat—FASN—telencephalon—epilepsy syndrome	0.00322	0.0357	CbGeAlD
Orlistat—ABHD16A—medulla oblongata—epilepsy syndrome	0.00322	0.0357	CbGeAlD
Orlistat—DAGLA—brain—epilepsy syndrome	0.00315	0.0349	CbGeAlD
Orlistat—PLA2G7—midbrain—epilepsy syndrome	0.00314	0.0348	CbGeAlD
Orlistat—PLA2G7—spinal cord—epilepsy syndrome	0.00306	0.0339	CbGeAlD
Orlistat—ABHD12—medulla oblongata—epilepsy syndrome	0.00302	0.0335	CbGeAlD
Orlistat—DAGLB—cerebellum—epilepsy syndrome	0.003	0.0333	CbGeAlD
Orlistat—ABHD16A—midbrain—epilepsy syndrome	0.00294	0.0326	CbGeAlD
Orlistat—ABHD16A—spinal cord—epilepsy syndrome	0.00287	0.0318	CbGeAlD
Orlistat—ABHD12—midbrain—epilepsy syndrome	0.00276	0.0306	CbGeAlD
Orlistat—ABHD12—spinal cord—epilepsy syndrome	0.00269	0.0298	CbGeAlD
Orlistat—FASN—medulla oblongata—epilepsy syndrome	0.00253	0.0281	CbGeAlD
Orlistat—DAGLB—brain—epilepsy syndrome	0.00244	0.0271	CbGeAlD
Orlistat—PNLIP—head—epilepsy syndrome	0.00239	0.0265	CbGeAlD
Orlistat—FASN—midbrain—epilepsy syndrome	0.00231	0.0257	CbGeAlD
Orlistat—ABHD16A—cerebellum—epilepsy syndrome	0.00228	0.0252	CbGeAlD
Orlistat—FASN—spinal cord—epilepsy syndrome	0.00226	0.025	CbGeAlD
Orlistat—ABHD12—cerebellum—epilepsy syndrome	0.00213	0.0237	CbGeAlD
Orlistat—PLA2G7—brain—epilepsy syndrome	0.00197	0.0219	CbGeAlD
Orlistat—FASN—cerebellum—epilepsy syndrome	0.00179	0.0199	CbGeAlD
Orlistat—ABHD12—brain—epilepsy syndrome	0.00173	0.0192	CbGeAlD
Orlistat—FASN—brain—epilepsy syndrome	0.00145	0.0161	CbGeAlD
Orlistat—PLA2G4A—medulla oblongata—epilepsy syndrome	0.00122	0.0135	CbGeAlD
Orlistat—PLA2G4A—midbrain—epilepsy syndrome	0.00111	0.0123	CbGeAlD
Orlistat—PLA2G4A—spinal cord—epilepsy syndrome	0.00109	0.012	CbGeAlD
Orlistat—PLA2G4A—nervous system—epilepsy syndrome	0.000915	0.0101	CbGeAlD
Orlistat—PLA2G4A—central nervous system—epilepsy syndrome	0.000881	0.00976	CbGeAlD
Orlistat—PLA2G4A—brain—epilepsy syndrome	0.000699	0.00775	CbGeAlD
Orlistat—CYP3A4—nervous system—epilepsy syndrome	0.000302	0.00335	CbGeAlD
Orlistat—CYP3A4—central nervous system—epilepsy syndrome	0.000291	0.00322	CbGeAlD
Orlistat—Nausea—Propofol—epilepsy syndrome	0.000108	0.000303	CcSEcCtD
Orlistat—Vomiting—Fosphenytoin—epilepsy syndrome	0.000108	0.000303	CcSEcCtD
Orlistat—Diarrhoea—Felbamate—epilepsy syndrome	0.000108	0.000303	CcSEcCtD
Orlistat—Vertigo—Pregabalin—epilepsy syndrome	0.000108	0.000302	CcSEcCtD
Orlistat—Body temperature increased—Lamotrigine—epilepsy syndrome	0.000108	0.000302	CcSEcCtD
Orlistat—Abdominal pain—Lamotrigine—epilepsy syndrome	0.000108	0.000302	CcSEcCtD
Orlistat—Dysgeusia—Gabapentin—epilepsy syndrome	0.000107	0.000302	CcSEcCtD
Orlistat—Dizziness—Diazepam—epilepsy syndrome	0.000107	0.000302	CcSEcCtD
Orlistat—Infection—Valproic Acid—epilepsy syndrome	0.000107	0.000302	CcSEcCtD
Orlistat—Rash—Fosphenytoin—epilepsy syndrome	0.000107	0.0003	CcSEcCtD
Orlistat—Dermatitis—Fosphenytoin—epilepsy syndrome	0.000107	0.0003	CcSEcCtD
Orlistat—Haemoglobin—Topiramate—epilepsy syndrome	0.000107	0.0003	CcSEcCtD
Orlistat—Asthenia—Clonazepam—epilepsy syndrome	0.000106	0.000299	CcSEcCtD
Orlistat—Back pain—Gabapentin—epilepsy syndrome	0.000106	0.000299	CcSEcCtD
Orlistat—Headache—Fosphenytoin—epilepsy syndrome	0.000106	0.000298	CcSEcCtD
Orlistat—Haemorrhage—Topiramate—epilepsy syndrome	0.000106	0.000298	CcSEcCtD
Orlistat—Hepatitis—Topiramate—epilepsy syndrome	0.000106	0.000298	CcSEcCtD
Orlistat—Nervous system disorder—Valproic Acid—epilepsy syndrome	0.000106	0.000298	CcSEcCtD
Orlistat—Palpitations—Pregabalin—epilepsy syndrome	0.000106	0.000297	CcSEcCtD
Orlistat—Asthenia—Phenytoin—epilepsy syndrome	0.000106	0.000297	CcSEcCtD
Orlistat—Nausea—Midazolam—epilepsy syndrome	0.000106	0.000297	CcSEcCtD
Orlistat—Muscle spasms—Gabapentin—epilepsy syndrome	0.000106	0.000297	CcSEcCtD
Orlistat—Diarrhoea—Zonisamide—epilepsy syndrome	0.000105	0.000296	CcSEcCtD
Orlistat—Pharyngitis—Topiramate—epilepsy syndrome	0.000105	0.000296	CcSEcCtD
Orlistat—Asthenia—Oxcarbazepine—epilepsy syndrome	0.000105	0.000296	CcSEcCtD
Orlistat—Pruritus—Clonazepam—epilepsy syndrome	0.000105	0.000295	CcSEcCtD
Orlistat—Vomiting—Vigabatrin—epilepsy syndrome	0.000105	0.000295	CcSEcCtD
Orlistat—Skin disorder—Valproic Acid—epilepsy syndrome	0.000105	0.000295	CcSEcCtD
Orlistat—Urinary tract disorder—Topiramate—epilepsy syndrome	0.000105	0.000295	CcSEcCtD
Orlistat—Oedema peripheral—Topiramate—epilepsy syndrome	0.000105	0.000294	CcSEcCtD
Orlistat—Hyperhidrosis—Valproic Acid—epilepsy syndrome	0.000104	0.000294	CcSEcCtD
Orlistat—Cough—Pregabalin—epilepsy syndrome	0.000104	0.000294	CcSEcCtD
Orlistat—Pruritus—Phenytoin—epilepsy syndrome	0.000104	0.000293	CcSEcCtD
Orlistat—Nausea—Levetiracetam—epilepsy syndrome	0.000104	0.000293	CcSEcCtD
Orlistat—Rash—Vigabatrin—epilepsy syndrome	0.000104	0.000293	CcSEcCtD
Orlistat—Dizziness—Felbamate—epilepsy syndrome	0.000104	0.000292	CcSEcCtD
Orlistat—Dermatitis—Vigabatrin—epilepsy syndrome	0.000104	0.000292	CcSEcCtD
Orlistat—Urethral disorder—Topiramate—epilepsy syndrome	0.000104	0.000292	CcSEcCtD
Orlistat—Pruritus—Oxcarbazepine—epilepsy syndrome	0.000104	0.000292	CcSEcCtD
Orlistat—Convulsion—Pregabalin—epilepsy syndrome	0.000104	0.000292	CcSEcCtD
Orlistat—Hypersensitivity—Carbamazepine—epilepsy syndrome	0.000104	0.000291	CcSEcCtD
Orlistat—Vision blurred—Gabapentin—epilepsy syndrome	0.000103	0.000291	CcSEcCtD
Orlistat—Headache—Vigabatrin—epilepsy syndrome	0.000103	0.000291	CcSEcCtD
Orlistat—Vomiting—Diazepam—epilepsy syndrome	0.000103	0.000291	CcSEcCtD
Orlistat—Rash—Diazepam—epilepsy syndrome	0.000102	0.000288	CcSEcCtD
Orlistat—Dermatitis—Diazepam—epilepsy syndrome	0.000102	0.000288	CcSEcCtD
Orlistat—Chest pain—Pregabalin—epilepsy syndrome	0.000102	0.000287	CcSEcCtD
Orlistat—Myalgia—Pregabalin—epilepsy syndrome	0.000102	0.000287	CcSEcCtD
Orlistat—Ill-defined disorder—Gabapentin—epilepsy syndrome	0.000102	0.000286	CcSEcCtD
Orlistat—Dizziness—Zonisamide—epilepsy syndrome	0.000102	0.000286	CcSEcCtD
Orlistat—Headache—Diazepam—epilepsy syndrome	0.000102	0.000286	CcSEcCtD
Orlistat—Anxiety—Pregabalin—epilepsy syndrome	0.000102	0.000286	CcSEcCtD
Orlistat—Diarrhoea—Clonazepam—epilepsy syndrome	0.000102	0.000286	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	0.000101	0.000285	CcSEcCtD
Orlistat—Asthenia—Carbamazepine—epilepsy syndrome	0.000101	0.000284	CcSEcCtD
Orlistat—Diarrhoea—Phenytoin—epilepsy syndrome	0.000101	0.000284	CcSEcCtD
Orlistat—Discomfort—Pregabalin—epilepsy syndrome	0.000101	0.000283	CcSEcCtD
Orlistat—Nausea—Fosphenytoin—epilepsy syndrome	0.000101	0.000283	CcSEcCtD
Orlistat—Diarrhoea—Oxcarbazepine—epilepsy syndrome	0.0001	0.000282	CcSEcCtD
Orlistat—Angioedema—Gabapentin—epilepsy syndrome	0.0001	0.000282	CcSEcCtD
Orlistat—Hypersensitivity—Lamotrigine—epilepsy syndrome	0.0001	0.000282	CcSEcCtD
Orlistat—Vomiting—Felbamate—epilepsy syndrome	0.0001	0.000281	CcSEcCtD
Orlistat—Dry mouth—Pregabalin—epilepsy syndrome	9.97e-05	0.00028	CcSEcCtD
Orlistat—Pruritus—Carbamazepine—epilepsy syndrome	9.96e-05	0.00028	CcSEcCtD
Orlistat—Rash—Felbamate—epilepsy syndrome	9.92e-05	0.000279	CcSEcCtD
Orlistat—Dermatitis—Felbamate—epilepsy syndrome	9.91e-05	0.000279	CcSEcCtD
Orlistat—Malaise—Gabapentin—epilepsy syndrome	9.9e-05	0.000278	CcSEcCtD
Orlistat—Vertigo—Gabapentin—epilepsy syndrome	9.86e-05	0.000277	CcSEcCtD
Orlistat—Headache—Felbamate—epilepsy syndrome	9.86e-05	0.000277	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	9.85e-05	0.000277	CcSEcCtD
Orlistat—Dizziness—Clonazepam—epilepsy syndrome	9.81e-05	0.000276	CcSEcCtD
Orlistat—Nausea—Vigabatrin—epilepsy syndrome	9.81e-05	0.000276	CcSEcCtD
Orlistat—Vomiting—Zonisamide—epilepsy syndrome	9.79e-05	0.000275	CcSEcCtD
Orlistat—Insomnia—Valproic Acid—epilepsy syndrome	9.77e-05	0.000275	CcSEcCtD
Orlistat—Oedema—Pregabalin—epilepsy syndrome	9.77e-05	0.000275	CcSEcCtD
Orlistat—Anaphylactic shock—Pregabalin—epilepsy syndrome	9.77e-05	0.000275	CcSEcCtD
Orlistat—Asthenia—Lamotrigine—epilepsy syndrome	9.76e-05	0.000274	CcSEcCtD
Orlistat—Dizziness—Phenytoin—epilepsy syndrome	9.75e-05	0.000274	CcSEcCtD
Orlistat—Rash—Zonisamide—epilepsy syndrome	9.71e-05	0.000273	CcSEcCtD
Orlistat—Infection—Pregabalin—epilepsy syndrome	9.71e-05	0.000273	CcSEcCtD
Orlistat—Paraesthesia—Valproic Acid—epilepsy syndrome	9.7e-05	0.000273	CcSEcCtD
Orlistat—Palpitations—Gabapentin—epilepsy syndrome	9.7e-05	0.000273	CcSEcCtD
Orlistat—Dermatitis—Zonisamide—epilepsy syndrome	9.7e-05	0.000273	CcSEcCtD
Orlistat—Dizziness—Oxcarbazepine—epilepsy syndrome	9.7e-05	0.000273	CcSEcCtD
Orlistat—Nausea—Diazepam—epilepsy syndrome	9.65e-05	0.000271	CcSEcCtD
Orlistat—Headache—Zonisamide—epilepsy syndrome	9.65e-05	0.000271	CcSEcCtD
Orlistat—Diarrhoea—Carbamazepine—epilepsy syndrome	9.63e-05	0.000271	CcSEcCtD
Orlistat—Pruritus—Lamotrigine—epilepsy syndrome	9.62e-05	0.000271	CcSEcCtD
Orlistat—Immune system disorder—Topiramate—epilepsy syndrome	9.58e-05	0.000269	CcSEcCtD
Orlistat—Nervous system disorder—Pregabalin—epilepsy syndrome	9.58e-05	0.000269	CcSEcCtD
Orlistat—Cough—Gabapentin—epilepsy syndrome	9.58e-05	0.000269	CcSEcCtD
Orlistat—Mediastinal disorder—Topiramate—epilepsy syndrome	9.56e-05	0.000269	CcSEcCtD
Orlistat—Dyspepsia—Valproic Acid—epilepsy syndrome	9.51e-05	0.000267	CcSEcCtD
Orlistat—Convulsion—Gabapentin—epilepsy syndrome	9.51e-05	0.000267	CcSEcCtD
Orlistat—Skin disorder—Pregabalin—epilepsy syndrome	9.49e-05	0.000267	CcSEcCtD
Orlistat—Hyperhidrosis—Pregabalin—epilepsy syndrome	9.44e-05	0.000266	CcSEcCtD
Orlistat—Vomiting—Clonazepam—epilepsy syndrome	9.44e-05	0.000265	CcSEcCtD
Orlistat—Decreased appetite—Valproic Acid—epilepsy syndrome	9.39e-05	0.000264	CcSEcCtD
Orlistat—Alopecia—Topiramate—epilepsy syndrome	9.37e-05	0.000264	CcSEcCtD
Orlistat—Vomiting—Phenytoin—epilepsy syndrome	9.37e-05	0.000264	CcSEcCtD
Orlistat—Rash—Clonazepam—epilepsy syndrome	9.36e-05	0.000263	CcSEcCtD
Orlistat—Dermatitis—Clonazepam—epilepsy syndrome	9.35e-05	0.000263	CcSEcCtD
Orlistat—Chest pain—Gabapentin—epilepsy syndrome	9.35e-05	0.000263	CcSEcCtD
Orlistat—Myalgia—Gabapentin—epilepsy syndrome	9.35e-05	0.000263	CcSEcCtD
Orlistat—Nausea—Felbamate—epilepsy syndrome	9.34e-05	0.000263	CcSEcCtD
Orlistat—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	9.33e-05	0.000262	CcSEcCtD
Orlistat—Vomiting—Oxcarbazepine—epilepsy syndrome	9.32e-05	0.000262	CcSEcCtD
Orlistat—Fatigue—Valproic Acid—epilepsy syndrome	9.32e-05	0.000262	CcSEcCtD
Orlistat—Anxiety—Gabapentin—epilepsy syndrome	9.31e-05	0.000262	CcSEcCtD
Orlistat—Dizziness—Carbamazepine—epilepsy syndrome	9.31e-05	0.000262	CcSEcCtD
Orlistat—Diarrhoea—Lamotrigine—epilepsy syndrome	9.3e-05	0.000262	CcSEcCtD
Orlistat—Headache—Clonazepam—epilepsy syndrome	9.3e-05	0.000261	CcSEcCtD
Orlistat—Rash—Phenytoin—epilepsy syndrome	9.29e-05	0.000261	CcSEcCtD
Orlistat—Mental disorder—Topiramate—epilepsy syndrome	9.29e-05	0.000261	CcSEcCtD
Orlistat—Dermatitis—Phenytoin—epilepsy syndrome	9.29e-05	0.000261	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	9.28e-05	0.000261	CcSEcCtD
Orlistat—Rash—Oxcarbazepine—epilepsy syndrome	9.25e-05	0.00026	CcSEcCtD
Orlistat—Pain—Valproic Acid—epilepsy syndrome	9.24e-05	0.00026	CcSEcCtD
Orlistat—Dermatitis—Oxcarbazepine—epilepsy syndrome	9.24e-05	0.00026	CcSEcCtD
Orlistat—Headache—Phenytoin—epilepsy syndrome	9.24e-05	0.00026	CcSEcCtD
Orlistat—Malnutrition—Topiramate—epilepsy syndrome	9.24e-05	0.00026	CcSEcCtD
Orlistat—Discomfort—Gabapentin—epilepsy syndrome	9.23e-05	0.00026	CcSEcCtD
Orlistat—Headache—Oxcarbazepine—epilepsy syndrome	9.19e-05	0.000258	CcSEcCtD
Orlistat—Nausea—Zonisamide—epilepsy syndrome	9.15e-05	0.000257	CcSEcCtD
Orlistat—Dry mouth—Gabapentin—epilepsy syndrome	9.14e-05	0.000257	CcSEcCtD
Orlistat—Flatulence—Topiramate—epilepsy syndrome	9.1e-05	0.000256	CcSEcCtD
Orlistat—Dysgeusia—Topiramate—epilepsy syndrome	9.04e-05	0.000254	CcSEcCtD
Orlistat—Dizziness—Lamotrigine—epilepsy syndrome	8.99e-05	0.000253	CcSEcCtD
Orlistat—Anaphylactic shock—Gabapentin—epilepsy syndrome	8.96e-05	0.000252	CcSEcCtD
Orlistat—Oedema—Gabapentin—epilepsy syndrome	8.96e-05	0.000252	CcSEcCtD
Orlistat—Vomiting—Carbamazepine—epilepsy syndrome	8.95e-05	0.000252	CcSEcCtD
Orlistat—Back pain—Topiramate—epilepsy syndrome	8.93e-05	0.000251	CcSEcCtD
Orlistat—Feeling abnormal—Valproic Acid—epilepsy syndrome	8.91e-05	0.00025	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	8.9e-05	0.00025	CcSEcCtD
Orlistat—Infection—Gabapentin—epilepsy syndrome	8.9e-05	0.00025	CcSEcCtD
Orlistat—Muscle spasms—Topiramate—epilepsy syndrome	8.88e-05	0.00025	CcSEcCtD
Orlistat—Rash—Carbamazepine—epilepsy syndrome	8.87e-05	0.000249	CcSEcCtD
Orlistat—Dermatitis—Carbamazepine—epilepsy syndrome	8.86e-05	0.000249	CcSEcCtD
Orlistat—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	8.84e-05	0.000248	CcSEcCtD
Orlistat—Insomnia—Pregabalin—epilepsy syndrome	8.84e-05	0.000248	CcSEcCtD
Orlistat—Nausea—Clonazepam—epilepsy syndrome	8.82e-05	0.000248	CcSEcCtD
Orlistat—Headache—Carbamazepine—epilepsy syndrome	8.82e-05	0.000248	CcSEcCtD
Orlistat—Nervous system disorder—Gabapentin—epilepsy syndrome	8.79e-05	0.000247	CcSEcCtD
Orlistat—Paraesthesia—Pregabalin—epilepsy syndrome	8.77e-05	0.000247	CcSEcCtD
Orlistat—Nausea—Phenytoin—epilepsy syndrome	8.76e-05	0.000246	CcSEcCtD
Orlistat—Nausea—Oxcarbazepine—epilepsy syndrome	8.71e-05	0.000245	CcSEcCtD
Orlistat—Vision blurred—Topiramate—epilepsy syndrome	8.7e-05	0.000245	CcSEcCtD
Orlistat—Skin disorder—Gabapentin—epilepsy syndrome	8.7e-05	0.000245	CcSEcCtD
Orlistat—Hyperhidrosis—Gabapentin—epilepsy syndrome	8.66e-05	0.000244	CcSEcCtD
Orlistat—Vomiting—Lamotrigine—epilepsy syndrome	8.65e-05	0.000243	CcSEcCtD
Orlistat—Urticaria—Valproic Acid—epilepsy syndrome	8.59e-05	0.000241	CcSEcCtD
Orlistat—Rash—Lamotrigine—epilepsy syndrome	8.57e-05	0.000241	CcSEcCtD
Orlistat—Ill-defined disorder—Topiramate—epilepsy syndrome	8.57e-05	0.000241	CcSEcCtD
Orlistat—Dermatitis—Lamotrigine—epilepsy syndrome	8.57e-05	0.000241	CcSEcCtD
Orlistat—Abdominal pain—Valproic Acid—epilepsy syndrome	8.54e-05	0.00024	CcSEcCtD
Orlistat—Body temperature increased—Valproic Acid—epilepsy syndrome	8.54e-05	0.00024	CcSEcCtD
Orlistat—Headache—Lamotrigine—epilepsy syndrome	8.52e-05	0.00024	CcSEcCtD
Orlistat—Decreased appetite—Pregabalin—epilepsy syndrome	8.49e-05	0.000239	CcSEcCtD
Orlistat—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	8.43e-05	0.000237	CcSEcCtD
Orlistat—Fatigue—Pregabalin—epilepsy syndrome	8.42e-05	0.000237	CcSEcCtD
Orlistat—Nausea—Carbamazepine—epilepsy syndrome	8.36e-05	0.000235	CcSEcCtD
Orlistat—Pain—Pregabalin—epilepsy syndrome	8.35e-05	0.000235	CcSEcCtD
Orlistat—Malaise—Topiramate—epilepsy syndrome	8.33e-05	0.000234	CcSEcCtD
Orlistat—Vertigo—Topiramate—epilepsy syndrome	8.3e-05	0.000233	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	8.16e-05	0.000229	CcSEcCtD
Orlistat—Palpitations—Topiramate—epilepsy syndrome	8.16e-05	0.000229	CcSEcCtD
Orlistat—Insomnia—Gabapentin—epilepsy syndrome	8.1e-05	0.000228	CcSEcCtD
Orlistat—Nausea—Lamotrigine—epilepsy syndrome	8.08e-05	0.000227	CcSEcCtD
Orlistat—Cough—Topiramate—epilepsy syndrome	8.06e-05	0.000227	CcSEcCtD
Orlistat—Feeling abnormal—Pregabalin—epilepsy syndrome	8.05e-05	0.000226	CcSEcCtD
Orlistat—Paraesthesia—Gabapentin—epilepsy syndrome	8.04e-05	0.000226	CcSEcCtD
Orlistat—Convulsion—Topiramate—epilepsy syndrome	8e-05	0.000225	CcSEcCtD
Orlistat—Gastrointestinal pain—Pregabalin—epilepsy syndrome	7.99e-05	0.000225	CcSEcCtD
Orlistat—Hypersensitivity—Valproic Acid—epilepsy syndrome	7.96e-05	0.000224	CcSEcCtD
Orlistat—Dyspepsia—Gabapentin—epilepsy syndrome	7.89e-05	0.000222	CcSEcCtD
Orlistat—Chest pain—Topiramate—epilepsy syndrome	7.86e-05	0.000221	CcSEcCtD
Orlistat—Myalgia—Topiramate—epilepsy syndrome	7.86e-05	0.000221	CcSEcCtD
Orlistat—Anxiety—Topiramate—epilepsy syndrome	7.84e-05	0.00022	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	7.81e-05	0.00022	CcSEcCtD
Orlistat—Decreased appetite—Gabapentin—epilepsy syndrome	7.79e-05	0.000219	CcSEcCtD
Orlistat—Discomfort—Topiramate—epilepsy syndrome	7.77e-05	0.000218	CcSEcCtD
Orlistat—Urticaria—Pregabalin—epilepsy syndrome	7.76e-05	0.000218	CcSEcCtD
Orlistat—Asthenia—Valproic Acid—epilepsy syndrome	7.75e-05	0.000218	CcSEcCtD
Orlistat—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	7.73e-05	0.000217	CcSEcCtD
Orlistat—Fatigue—Gabapentin—epilepsy syndrome	7.72e-05	0.000217	CcSEcCtD
Orlistat—Abdominal pain—Pregabalin—epilepsy syndrome	7.72e-05	0.000217	CcSEcCtD
Orlistat—Body temperature increased—Pregabalin—epilepsy syndrome	7.72e-05	0.000217	CcSEcCtD
Orlistat—Dry mouth—Topiramate—epilepsy syndrome	7.69e-05	0.000216	CcSEcCtD
Orlistat—Pain—Gabapentin—epilepsy syndrome	7.66e-05	0.000215	CcSEcCtD
Orlistat—Pruritus—Valproic Acid—epilepsy syndrome	7.65e-05	0.000215	CcSEcCtD
Orlistat—Oedema—Topiramate—epilepsy syndrome	7.54e-05	0.000212	CcSEcCtD
Orlistat—Infection—Topiramate—epilepsy syndrome	7.49e-05	0.000211	CcSEcCtD
Orlistat—Diarrhoea—Valproic Acid—epilepsy syndrome	7.39e-05	0.000208	CcSEcCtD
Orlistat—Nervous system disorder—Topiramate—epilepsy syndrome	7.39e-05	0.000208	CcSEcCtD
Orlistat—Feeling abnormal—Gabapentin—epilepsy syndrome	7.38e-05	0.000208	CcSEcCtD
Orlistat—Gastrointestinal pain—Gabapentin—epilepsy syndrome	7.33e-05	0.000206	CcSEcCtD
Orlistat—Skin disorder—Topiramate—epilepsy syndrome	7.32e-05	0.000206	CcSEcCtD
Orlistat—Hyperhidrosis—Topiramate—epilepsy syndrome	7.29e-05	0.000205	CcSEcCtD
Orlistat—Hypersensitivity—Pregabalin—epilepsy syndrome	7.2e-05	0.000202	CcSEcCtD
Orlistat—Dizziness—Valproic Acid—epilepsy syndrome	7.15e-05	0.000201	CcSEcCtD
Orlistat—Urticaria—Gabapentin—epilepsy syndrome	7.12e-05	0.0002	CcSEcCtD
Orlistat—Abdominal pain—Gabapentin—epilepsy syndrome	7.08e-05	0.000199	CcSEcCtD
Orlistat—Body temperature increased—Gabapentin—epilepsy syndrome	7.08e-05	0.000199	CcSEcCtD
Orlistat—Asthenia—Pregabalin—epilepsy syndrome	7.01e-05	0.000197	CcSEcCtD
Orlistat—Pruritus—Pregabalin—epilepsy syndrome	6.91e-05	0.000194	CcSEcCtD
Orlistat—Vomiting—Valproic Acid—epilepsy syndrome	6.87e-05	0.000193	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	6.87e-05	0.000193	CcSEcCtD
Orlistat—Insomnia—Topiramate—epilepsy syndrome	6.82e-05	0.000192	CcSEcCtD
Orlistat—Rash—Valproic Acid—epilepsy syndrome	6.81e-05	0.000192	CcSEcCtD
Orlistat—Dermatitis—Valproic Acid—epilepsy syndrome	6.81e-05	0.000191	CcSEcCtD
Orlistat—Headache—Valproic Acid—epilepsy syndrome	6.77e-05	0.00019	CcSEcCtD
Orlistat—Paraesthesia—Topiramate—epilepsy syndrome	6.77e-05	0.00019	CcSEcCtD
Orlistat—Diarrhoea—Pregabalin—epilepsy syndrome	6.68e-05	0.000188	CcSEcCtD
Orlistat—Dyspepsia—Topiramate—epilepsy syndrome	6.63e-05	0.000187	CcSEcCtD
Orlistat—Hypersensitivity—Gabapentin—epilepsy syndrome	6.6e-05	0.000186	CcSEcCtD
Orlistat—Decreased appetite—Topiramate—epilepsy syndrome	6.55e-05	0.000184	CcSEcCtD
Orlistat—Gastrointestinal disorder—Topiramate—epilepsy syndrome	6.51e-05	0.000183	CcSEcCtD
Orlistat—Fatigue—Topiramate—epilepsy syndrome	6.5e-05	0.000183	CcSEcCtD
Orlistat—Dizziness—Pregabalin—epilepsy syndrome	6.46e-05	0.000182	CcSEcCtD
Orlistat—Pain—Topiramate—epilepsy syndrome	6.45e-05	0.000181	CcSEcCtD
Orlistat—Asthenia—Gabapentin—epilepsy syndrome	6.43e-05	0.000181	CcSEcCtD
Orlistat—Nausea—Valproic Acid—epilepsy syndrome	6.42e-05	0.00018	CcSEcCtD
Orlistat—Pruritus—Gabapentin—epilepsy syndrome	6.34e-05	0.000178	CcSEcCtD
Orlistat—Vomiting—Pregabalin—epilepsy syndrome	6.21e-05	0.000175	CcSEcCtD
Orlistat—Feeling abnormal—Topiramate—epilepsy syndrome	6.21e-05	0.000175	CcSEcCtD
Orlistat—Gastrointestinal pain—Topiramate—epilepsy syndrome	6.16e-05	0.000173	CcSEcCtD
Orlistat—Rash—Pregabalin—epilepsy syndrome	6.16e-05	0.000173	CcSEcCtD
Orlistat—Dermatitis—Pregabalin—epilepsy syndrome	6.15e-05	0.000173	CcSEcCtD
Orlistat—Diarrhoea—Gabapentin—epilepsy syndrome	6.13e-05	0.000172	CcSEcCtD
Orlistat—Headache—Pregabalin—epilepsy syndrome	6.12e-05	0.000172	CcSEcCtD
Orlistat—Urticaria—Topiramate—epilepsy syndrome	5.99e-05	0.000168	CcSEcCtD
Orlistat—Abdominal pain—Topiramate—epilepsy syndrome	5.96e-05	0.000168	CcSEcCtD
Orlistat—Body temperature increased—Topiramate—epilepsy syndrome	5.96e-05	0.000168	CcSEcCtD
Orlistat—Dizziness—Gabapentin—epilepsy syndrome	5.92e-05	0.000167	CcSEcCtD
Orlistat—Nausea—Pregabalin—epilepsy syndrome	5.8e-05	0.000163	CcSEcCtD
Orlistat—Vomiting—Gabapentin—epilepsy syndrome	5.7e-05	0.00016	CcSEcCtD
Orlistat—Rash—Gabapentin—epilepsy syndrome	5.65e-05	0.000159	CcSEcCtD
Orlistat—Dermatitis—Gabapentin—epilepsy syndrome	5.64e-05	0.000159	CcSEcCtD
Orlistat—Headache—Gabapentin—epilepsy syndrome	5.61e-05	0.000158	CcSEcCtD
Orlistat—Hypersensitivity—Topiramate—epilepsy syndrome	5.55e-05	0.000156	CcSEcCtD
Orlistat—Asthenia—Topiramate—epilepsy syndrome	5.41e-05	0.000152	CcSEcCtD
Orlistat—Pruritus—Topiramate—epilepsy syndrome	5.33e-05	0.00015	CcSEcCtD
Orlistat—Nausea—Gabapentin—epilepsy syndrome	5.32e-05	0.00015	CcSEcCtD
Orlistat—Diarrhoea—Topiramate—epilepsy syndrome	5.16e-05	0.000145	CcSEcCtD
Orlistat—Dizziness—Topiramate—epilepsy syndrome	4.98e-05	0.00014	CcSEcCtD
Orlistat—Vomiting—Topiramate—epilepsy syndrome	4.79e-05	0.000135	CcSEcCtD
Orlistat—Rash—Topiramate—epilepsy syndrome	4.75e-05	0.000134	CcSEcCtD
Orlistat—Dermatitis—Topiramate—epilepsy syndrome	4.75e-05	0.000133	CcSEcCtD
Orlistat—Headache—Topiramate—epilepsy syndrome	4.72e-05	0.000133	CcSEcCtD
Orlistat—Nausea—Topiramate—epilepsy syndrome	4.48e-05	0.000126	CcSEcCtD
Orlistat—PLA2G4A—Signaling Pathways—SSTR1—epilepsy syndrome	2.5e-05	0.000119	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PRKCB—epilepsy syndrome	2.5e-05	0.000119	CbGpPWpGaD
Orlistat—FASN—Disease—NOS2—epilepsy syndrome	2.49e-05	0.000118	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL6ST—epilepsy syndrome	2.49e-05	0.000118	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—epilepsy syndrome	2.48e-05	0.000118	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—ALB—epilepsy syndrome	2.48e-05	0.000118	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GRM3—epilepsy syndrome	2.45e-05	0.000116	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GRM4—epilepsy syndrome	2.45e-05	0.000116	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—FGF2—epilepsy syndrome	2.43e-05	0.000115	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—FGF2—epilepsy syndrome	2.43e-05	0.000115	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—DUSP4—epilepsy syndrome	2.41e-05	0.000114	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SSTR2—epilepsy syndrome	2.41e-05	0.000114	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PLAU—epilepsy syndrome	2.4e-05	0.000114	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—epilepsy syndrome	2.39e-05	0.000114	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CHRM3—epilepsy syndrome	2.37e-05	0.000112	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—KCNJ11—epilepsy syndrome	2.37e-05	0.000112	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GRM8—epilepsy syndrome	2.33e-05	0.00011	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PGF—epilepsy syndrome	2.33e-05	0.00011	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCR2—epilepsy syndrome	2.32e-05	0.00011	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—SST—epilepsy syndrome	2.32e-05	0.00011	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP2D6—epilepsy syndrome	2.31e-05	0.00011	CbGpPWpGaD
Orlistat—FASN—Metabolism—AGT—epilepsy syndrome	2.29e-05	0.000109	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP2D6—epilepsy syndrome	2.28e-05	0.000108	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—POMC—epilepsy syndrome	2.27e-05	0.000108	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—ADRA2A—epilepsy syndrome	2.27e-05	0.000108	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—RELA—epilepsy syndrome	2.25e-05	0.000107	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—RELA—epilepsy syndrome	2.25e-05	0.000107	CbGpPWpGaD
Orlistat—FASN—Metabolism—APOE—epilepsy syndrome	2.24e-05	0.000106	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PRKCB—epilepsy syndrome	2.24e-05	0.000106	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCL2—epilepsy syndrome	2.23e-05	0.000106	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—OPRD1—epilepsy syndrome	2.22e-05	0.000105	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GNAO1—epilepsy syndrome	2.22e-05	0.000105	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MTOR—epilepsy syndrome	2.21e-05	0.000105	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MTOR—epilepsy syndrome	2.21e-05	0.000105	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—NOS2—epilepsy syndrome	2.21e-05	0.000105	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	2.2e-05	0.000105	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCL12—epilepsy syndrome	2.18e-05	0.000104	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—BDKRB2—epilepsy syndrome	2.18e-05	0.000104	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTGS2—epilepsy syndrome	2.17e-05	0.000103	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	2.16e-05	0.000102	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CNR1—epilepsy syndrome	2.14e-05	0.000102	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PLCB1—epilepsy syndrome	2.13e-05	0.000101	CbGpPWpGaD
Orlistat—CYP3A4—Phase 1 - Functionalization of compounds—POMC—epilepsy syndrome	2.13e-05	0.000101	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCR7—epilepsy syndrome	2.13e-05	0.000101	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PDYN—epilepsy syndrome	2.13e-05	0.000101	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GRM1—epilepsy syndrome	2.13e-05	0.000101	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CHRM1—epilepsy syndrome	2.13e-05	0.000101	CbGpPWpGaD
Orlistat—PNLIP—Disease—SRC—epilepsy syndrome	2.09e-05	9.94e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—HTR7—epilepsy syndrome	2.09e-05	9.92e-05	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—AKT1—epilepsy syndrome	2.05e-05	9.74e-05	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—AKT1—epilepsy syndrome	2.05e-05	9.74e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CASP3—epilepsy syndrome	2.03e-05	9.65e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CASP3—epilepsy syndrome	2.03e-05	9.65e-05	CbGpPWpGaD
Orlistat—FASN—Disease—FGF2—epilepsy syndrome	2.03e-05	9.64e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—HBEGF—epilepsy syndrome	2.03e-05	9.63e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—FGF2—epilepsy syndrome	2.01e-05	9.55e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GFAP—epilepsy syndrome	2e-05	9.5e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GAL—epilepsy syndrome	2e-05	9.5e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT3—epilepsy syndrome	1.99e-05	9.45e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CHRM3—epilepsy syndrome	1.98e-05	9.39e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CASP2—epilepsy syndrome	1.98e-05	9.39e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GRM5—epilepsy syndrome	1.98e-05	9.39e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—JUN—epilepsy syndrome	1.97e-05	9.37e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—JUN—epilepsy syndrome	1.97e-05	9.37e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ABCG2—epilepsy syndrome	1.93e-05	9.15e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—POMC—epilepsy syndrome	1.92e-05	9.13e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MMP9—epilepsy syndrome	1.92e-05	9.12e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MMP9—epilepsy syndrome	1.92e-05	9.12e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CX3CR1—epilepsy syndrome	1.9e-05	9e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP2C19—epilepsy syndrome	1.88e-05	8.92e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP11A1—epilepsy syndrome	1.87e-05	8.87e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—RELA—epilepsy syndrome	1.87e-05	8.86e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—AKT1—epilepsy syndrome	1.86e-05	8.84e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AKT1—epilepsy syndrome	1.86e-05	8.84e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CHRM2—epilepsy syndrome	1.86e-05	8.83e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—BDKRB1—epilepsy syndrome	1.86e-05	8.83e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CX3CL1—epilepsy syndrome	1.86e-05	8.83e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—ALB—epilepsy syndrome	1.86e-05	8.81e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	1.85e-05	8.8e-05	CbGpPWpGaD
Orlistat—FASN—Disease—MTOR—epilepsy syndrome	1.85e-05	8.78e-05	CbGpPWpGaD
Orlistat—FASN—Disease—PTGS2—epilepsy syndrome	1.83e-05	8.7e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MTOR—epilepsy syndrome	1.83e-05	8.69e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CDC42—epilepsy syndrome	1.82e-05	8.62e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GABBR1—epilepsy syndrome	1.81e-05	8.59e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	1.78e-05	8.45e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—SRC—epilepsy syndrome	1.77e-05	8.4e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SRC—epilepsy syndrome	1.77e-05	8.4e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CA13—epilepsy syndrome	1.76e-05	8.36e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AVP—epilepsy syndrome	1.76e-05	8.35e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—ALB—epilepsy syndrome	1.75e-05	8.33e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HRH3—epilepsy syndrome	1.73e-05	8.23e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—VEGFA—epilepsy syndrome	1.72e-05	8.19e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—VEGFA—epilepsy syndrome	1.72e-05	8.19e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—OPRM1—epilepsy syndrome	1.71e-05	8.11e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	1.69e-05	8.02e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP2D6—epilepsy syndrome	1.69e-05	8e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CASP3—epilepsy syndrome	1.68e-05	7.99e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—JUN—epilepsy syndrome	1.64e-05	7.76e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCR3—epilepsy syndrome	1.61e-05	7.65e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ADRA2A—epilepsy syndrome	1.6e-05	7.62e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—BCHE—epilepsy syndrome	1.6e-05	7.58e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MMP9—epilepsy syndrome	1.59e-05	7.55e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—epilepsy syndrome	1.58e-05	7.52e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NPY—epilepsy syndrome	1.57e-05	7.46e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ATP2A2—epilepsy syndrome	1.57e-05	7.46e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTGS2—epilepsy syndrome	1.53e-05	7.29e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SLC2A1—epilepsy syndrome	1.52e-05	7.24e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CRH—epilepsy syndrome	1.52e-05	7.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HSPB1—epilepsy syndrome	1.52e-05	7.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—OXT—epilepsy syndrome	1.52e-05	7.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL2—epilepsy syndrome	1.52e-05	7.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCL3—epilepsy syndrome	1.52e-05	7.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PLCB1—epilepsy syndrome	1.51e-05	7.16e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TH—epilepsy syndrome	1.5e-05	7.13e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCR5—epilepsy syndrome	1.5e-05	7.1e-05	CbGpPWpGaD
Orlistat—FASN—Disease—SRC—epilepsy syndrome	1.48e-05	7.04e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.48e-05	7.02e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SRC—epilepsy syndrome	1.47e-05	6.96e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—HTR2A—epilepsy syndrome	1.46e-05	6.95e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VEGFA—epilepsy syndrome	1.43e-05	6.78e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTK2B—epilepsy syndrome	1.41e-05	6.69e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TSC1—epilepsy syndrome	1.41e-05	6.69e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AGT—epilepsy syndrome	1.39e-05	6.59e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NTRK2—epilepsy syndrome	1.37e-05	6.51e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SST—epilepsy syndrome	1.37e-05	6.51e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCR2—epilepsy syndrome	1.37e-05	6.51e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—DUSP6—epilepsy syndrome	1.36e-05	6.45e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADRA2A—epilepsy syndrome	1.34e-05	6.37e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PLAT—epilepsy syndrome	1.34e-05	6.34e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CERS1—epilepsy syndrome	1.33e-05	6.33e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GLUD1—epilepsy syndrome	1.33e-05	6.33e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—L2HGDH—epilepsy syndrome	1.33e-05	6.33e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ADK—epilepsy syndrome	1.33e-05	6.33e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PDXK—epilepsy syndrome	1.33e-05	6.33e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—FAR1—epilepsy syndrome	1.33e-05	6.33e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—SRC—epilepsy syndrome	1.31e-05	6.24e-05	CbGpPWpGaD
Orlistat—PNLIP—Disease—AKT1—epilepsy syndrome	1.3e-05	6.18e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL12—epilepsy syndrome	1.29e-05	6.12e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—BDKRB2—epilepsy syndrome	1.29e-05	6.12e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PRKCB—epilepsy syndrome	1.28e-05	6.09e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VEGFA—epilepsy syndrome	1.28e-05	6.07e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6ST—epilepsy syndrome	1.28e-05	6.07e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—JUNB—epilepsy syndrome	1.27e-05	6.01e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CNR1—epilepsy syndrome	1.27e-05	6.01e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PLCB1—epilepsy syndrome	1.26e-05	5.98e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—HMOX1—epilepsy syndrome	1.25e-05	5.95e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CAT—epilepsy syndrome	1.24e-05	5.87e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HTR7—epilepsy syndrome	1.23e-05	5.86e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—EPM2A—epilepsy syndrome	1.22e-05	5.79e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NHLRC1—epilepsy syndrome	1.22e-05	5.79e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GAMT—epilepsy syndrome	1.22e-05	5.79e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PNPO—epilepsy syndrome	1.22e-05	5.79e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ABCB1—epilepsy syndrome	1.2e-05	5.71e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HBEGF—epilepsy syndrome	1.2e-05	5.69e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT3—epilepsy syndrome	1.18e-05	5.58e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—POMC—epilepsy syndrome	1.17e-05	5.55e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADAM10—epilepsy syndrome	1.15e-05	5.45e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCL2—epilepsy syndrome	1.14e-05	5.43e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CA4—epilepsy syndrome	1.13e-05	5.38e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—QDPR—epilepsy syndrome	1.13e-05	5.38e-05	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—POMC—epilepsy syndrome	1.13e-05	5.37e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GPX1—epilepsy syndrome	1.12e-05	5.31e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AKT1—epilepsy syndrome	1.1e-05	5.22e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AKT1—epilepsy syndrome	1.1e-05	5.22e-05	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AKT1—epilepsy syndrome	1.09e-05	5.18e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—S100B—epilepsy syndrome	1.09e-05	5.16e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SOCS3—epilepsy syndrome	1.08e-05	5.11e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDC42—epilepsy syndrome	1.07e-05	5.09e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—COX3—epilepsy syndrome	1.07e-05	5.06e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AVP—epilepsy syndrome	1.04e-05	4.93e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PFKL—epilepsy syndrome	1.01e-05	4.8e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC6A8—epilepsy syndrome	1.01e-05	4.8e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CACNA2D2—epilepsy syndrome	1.01e-05	4.8e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLCO1A2—epilepsy syndrome	1.01e-05	4.8e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—KCNB1—epilepsy syndrome	1.01e-05	4.8e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HES1—epilepsy syndrome	9.83e-06	4.66e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AGT—epilepsy syndrome	9.81e-06	4.66e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—APOE—epilepsy syndrome	9.61e-06	4.56e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FYN—epilepsy syndrome	9.55e-06	4.54e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—H2AFX—epilepsy syndrome	9.52e-06	4.52e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MEF2C—epilepsy syndrome	9.5e-06	4.51e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—UPB1—epilepsy syndrome	9.25e-06	4.39e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NEU1—epilepsy syndrome	9.25e-06	4.39e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ATIC—epilepsy syndrome	9.25e-06	4.39e-05	CbGpPWpGaD
Orlistat—FASN—Disease—AKT1—epilepsy syndrome	9.21e-06	4.37e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—YWHAZ—epilepsy syndrome	9.18e-06	4.36e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AKT1—epilepsy syndrome	9.12e-06	4.33e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NGF—epilepsy syndrome	9.08e-06	4.31e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HSD17B4—epilepsy syndrome	8.9e-06	4.23e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCR5—epilepsy syndrome	8.83e-06	4.19e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HTR2A—epilepsy syndrome	8.65e-06	4.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPP1R3C—epilepsy syndrome	8.6e-06	4.08e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GBE1—epilepsy syndrome	8.6e-06	4.08e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—POMC—epilepsy syndrome	8.26e-06	3.92e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TSC2—epilepsy syndrome	8.21e-06	3.9e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AGT—epilepsy syndrome	8.2e-06	3.89e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—AKT1—epilepsy syndrome	8.16e-06	3.88e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ASAH1—epilepsy syndrome	8.08e-06	3.84e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APOE—epilepsy syndrome	8.04e-06	3.82e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KDR—epilepsy syndrome	7.87e-06	3.74e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—STXBP1—epilepsy syndrome	7.86e-06	3.73e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—AKT1—epilepsy syndrome	7.71e-06	3.66e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NT5E—epilepsy syndrome	7.66e-06	3.64e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALAD—epilepsy syndrome	7.66e-06	3.64e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PRKCB—epilepsy syndrome	7.58e-06	3.6e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6ST—epilepsy syndrome	7.55e-06	3.58e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ALB—epilepsy syndrome	7.53e-06	3.57e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CACNA1A—epilepsy syndrome	7.31e-06	3.47e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALDH7A1—epilepsy syndrome	7.31e-06	3.47e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ST3GAL3—epilepsy syndrome	7.15e-06	3.4e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ADSL—epilepsy syndrome	7.01e-06	3.33e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—POMC—epilepsy syndrome	6.9e-06	3.28e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GLUL—epilepsy syndrome	6.87e-06	3.26e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCL2—epilepsy syndrome	6.76e-06	3.21e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	6.75e-06	3.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS2—epilepsy syndrome	6.59e-06	3.13e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	6.31e-06	3e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AQP1—epilepsy syndrome	6.13e-06	2.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGF2—epilepsy syndrome	6.11e-06	2.9e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RELA—epilepsy syndrome	5.67e-06	2.69e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MTOR—epilepsy syndrome	5.56e-06	2.64e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	5.54e-06	2.63e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	5.54e-06	2.63e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CASP3—epilepsy syndrome	5.11e-06	2.43e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—JUN—epilepsy syndrome	4.97e-06	2.36e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP9—epilepsy syndrome	4.83e-06	2.29e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT1—epilepsy syndrome	4.69e-06	2.22e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	4.52e-06	2.14e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SRC—epilepsy syndrome	4.45e-06	2.11e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	4.4e-06	2.09e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	4.37e-06	2.08e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFA—epilepsy syndrome	4.34e-06	2.06e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	3.95e-06	1.87e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	3.76e-06	1.78e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—BCHE—epilepsy syndrome	3.74e-06	1.78e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	3.57e-06	1.69e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	3.53e-06	1.68e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TH—epilepsy syndrome	3.52e-06	1.67e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKT1—epilepsy syndrome	3.31e-06	1.57e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	2.94e-06	1.39e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CAT—epilepsy syndrome	2.9e-06	1.38e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	2.82e-06	1.34e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT1—epilepsy syndrome	2.77e-06	1.31e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GPX1—epilepsy syndrome	2.62e-06	1.24e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AGT—epilepsy syndrome	2.3e-06	1.09e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—APOE—epilepsy syndrome	2.25e-06	1.07e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—POMC—epilepsy syndrome	1.93e-06	9.18e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALB—epilepsy syndrome	1.76e-06	8.37e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	1.54e-06	7.32e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKT1—epilepsy syndrome	7.75e-07	3.68e-06	CbGpPWpGaD
